SLC22A12 and hyperuricemia: Moreover, a single-arm, open-label, prospective study [34] is currently underway, aiming to observe the effects of URAT1 inhibitor on parameters related to renal injury in patients with Type 2 DKD and hyperuricemia who switched from febuxostat to dotinurad.